高剂量维生素D未能预防克罗恩病术后复发:随机安慰剂对照试验
一项多中心随机安慰剂对照试验纳入回结肠切除吻合术后的克罗恩病患者,每周口服25,000 IU维生素D或安慰剂共26周。
要点
- 高剂量维生素D未降低克罗恩病术后26周内镜或临床复发风险。
- 维生素D组血清25羟维生素D中位数从42升至81 nmol/L,安慰剂组维持43 nmol/L。
核心结论
- 与安慰剂相比,高剂量维生素D未降低回结肠切除吻合术后克罗恩病患者的内镜或临床复发率。
研究设计与样本
- 随机、安慰剂对照试验,在荷兰和比利时的17家医院进行,2014年2月至2017年6月。
- 纳入回结肠切除吻合术后的克罗恩病患者,随机分为每周口服25,000 IU维生素D组(n=72)或安慰剂组(n=71),共26周。
- 主要终点为26周时盲法评估的内镜复发(改良Rutgeerts评分≥i2b)。
主要发现
- 两组不良事件均少。
关键数值与推荐
- 内镜复发定义:改良Rutgeerts评分≥i2b。
- 临床复发定义:克罗恩病活动指数≥220。
- 维生素D剂量:每周口服25,000 IU,持续26周。
临床怎么用
- 对于回结肠切除吻合术后的克罗恩病患者,不应仅以预防复发为目的常规使用高剂量维生素D。
- 术后仍需根据内镜和临床指标监测复发,而非依赖高剂量维生素D补充。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Vitamin D deficiency is common in Crohn's disease (CD). High-dose vitamin D had anti-inflammatory effects in preclinical studies and trials of patients with CD. We performed a randomized trial to determine whether high-dose vitamin D prevents postoperative recurrence of CD after ileocolonic resection. METHODS: Patients with CD after ileocolonic resection with ileocolonic anastomosis were assigned randomly to groups given weekly 25,000 IU oral vitamin D (n = 72) or placebo (n = 71) for 26 weeks, at 17 hospitals in The Netherlands and Belgium, from February 2014 through June 2017. Patients were assessed at baseline and at weeks 2, 6, 12, and 26 for laboratory and clinical parameters, and underwent ileocolonoscopy at 26 weeks. The primary end point was endoscopic recurrence (modified Rutgeerts score, ≥i2b, as assessed by blinded readers) at 26 weeks. Secondary end points included clinical recurrence (Crohn's disease activity index, ≥220), quality of life (measured by the 36-Item Short Form Health Survey, Inflammatory Bowel Disease Questionnaire, and EuroQol, a 5-dimension questionnaire), and outcomes associated with the baseline serum concentration of vitamin D. RESULTS: In the vitamin D group, serum levels of 25-hydroxy vitamin D increased from a median of 42 nmol/L at baseline to 81 nmol/L at week 26 (P < .00001), whereas levels did not change significantly in the placebo group and remained unchanged at 43 nmol/L. In the intention-to-treat analysis, the proportion of patients with endoscopic recurrence at 26 weeks did not differ significantly between the vitamin D vs the placebo group (58% vs 66%; P = .37). The cumulative rate of clinical recurrence did not differ significantly between the groups (18.1% in the vitamin D group vs 18.3% in the placebo group; P = .91). Quality of life improved slightly over time in both groups, but did not differ significantly between groups (P = .07). There were few adverse events in either group. CONCLUSIONS: High-dose vitamin D, compared with placebo, did not reduce the incidence of postoperative endoscopic or clinical recurrence of CD in patients who underwent ileocolonic resection with ileocolonic anastomosis. ClinicalTrials.gov no: NCT02010762.
引用
- de Bruyn JR, Bossuyt P, Ferrante M, et al. High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2020. PMID: 32461138. doi:10.1016/j.cgh.2020.05.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。